O	0	1	[
O	1	11	Evaluation
O	12	14	on
O	15	18	the
O	19	25	effect
O	26	28	of
O	29	41	intervention
O	42	51	regarding
B-intervention	52	58	breast
I-intervention	59	63	self
I-intervention	63	64	-
I-intervention	64	75	examination
O	76	79	for
O	80	90	decreasing
O	91	97	breast
O	98	104	cancer
O	105	114	mortality
O	114	115	]
O	115	116	.

O	117	118	A
O	119	129	randomized
O	130	135	trial
O	136	138	of
O	139	145	breast
O	146	150	self
O	150	151	-
O	151	162	examination
O	163	164	(
O	164	167	BSE
O	167	168	)
O	169	176	Program
O	177	180	was
O	181	188	carried
O	189	192	out
O	193	195	to
O	196	204	evaluate
O	205	212	whether
O	213	216	the
O	217	226	intensive
O	227	230	BSE
O	231	236	could
O	237	243	reduce
O	244	247	the
O	248	254	number
O	255	257	of
O	258	264	deaths
O	265	270	among
O	271	276	women
O	277	281	from
O	282	288	breast
O	289	295	cancer
O	295	296	.

O	297	301	This
O	302	307	study
O	308	311	was
O	312	313	a
O	314	324	randomized
O	325	335	controlled
O	336	341	trial
O	342	343	(
O	343	346	RCT
O	346	347	)
O	347	348	.

O	349	350	A
O	351	356	total
O	357	359	of
B-total-participants	360	363	266
I-total-participants	364	367	064
O	368	373	women
O	374	375	(
O	375	378	age
O	379	381	of
B-age	382	384	30
I-age	385	387	to
I-age	388	390	64
I-age	391	396	years
O	396	397	)
O	398	408	associated
O	409	413	with
O	414	417	519
O	418	425	textile
O	426	435	factories
O	436	438	in
B-location	439	447	Shanghai
O	448	451	had
O	452	456	been
O	457	465	randomly
O	466	474	assigned
O	475	477	to
O	478	479	a
O	480	483	BSE
O	484	489	group
O	490	491	(
B-intervention-participants	491	494	132
I-intervention-participants	495	498	979
O	499	504	women
O	504	505	)
O	506	508	or
O	509	510	a
B-control	511	518	control
I-control	519	524	group
O	525	526	(
B-control-participants	526	529	133
I-control-participants	530	533	085
O	534	539	women
O	539	540	)
O	541	546	since
O	547	551	1989
O	551	552	.

O	553	560	Initial
O	561	572	instruction
O	573	575	in
O	576	579	BSE
O	580	585	group
O	586	591	would
O	592	599	include
O	600	613	demonstration
O	614	616	of
O	617	623	proper
O	624	633	palpation
O	634	644	techniques
O	645	648	and
O	649	652	was
O	653	661	followed
O	662	664	by
O	665	666	2
O	667	680	reinforcement
O	681	689	sessions
O	690	696	during
O	697	700	the
O	701	711	subsequent
O	712	713	4
O	714	719	years
O	720	729	including
O	730	735	video
O	736	741	shows
O	741	742	,
O	743	746	BSE
O	747	758	instruction
O	759	767	sessions
O	768	771	and
O	772	775	BSE
O	776	784	practice
O	785	790	under
O	791	798	medical
O	799	810	supervision
O	810	811	.

O	812	817	These
O	818	828	activities
O	829	833	were
O	834	843	continued
O	844	847	for
O	848	849	5
O	850	855	years
O	855	856	.

O	857	867	Attendance
O	868	870	at
O	871	874	all
O	875	881	events
O	882	885	was
O	886	894	recorded
O	894	895	.

O	896	899	The
O	900	906	cohort
O	907	910	was
O	911	919	followed
O	920	927	through
O	928	932	July
O	933	937	2000
O	938	941	for
O	942	953	development
O	954	956	of
O	957	963	breast
O	964	972	diseases
O	972	973	,
O	974	977	and
O	978	981	the
O	982	988	breast
O	989	995	cancer
O	996	1001	cases
O	1002	1006	were
O	1007	1015	followed
O	1016	1023	through
O	1024	1028	2001
O	1029	1032	for
O	1033	1038	vital
O	1039	1045	status
O	1045	1046	.

O	1047	1051	Data
O	1052	1060	analysis
O	1061	1068	methods
O	1069	1073	used
O	1074	1079	would
O	1080	1087	include
O	1088	1094	Kaplan
O	1094	1095	-
O	1095	1100	Meier
O	1101	1106	plots
O	1106	1107	,
O	1108	1111	log
O	1111	1112	-
O	1112	1116	rank
O	1117	1121	test
O	1122	1125	and
O	1126	1129	Cox
O	1130	1138	modeling
O	1138	1139	.

O	1140	1145	Among
O	1146	1151	women
O	1152	1157	under
O	1158	1169	instruction
O	1169	1170	,
B-iv-bin-abs	1171	1174	864
B-outcome	1175	1181	breast
I-outcome	1182	1189	cancers
O	1190	1198	detected
O	1199	1202	and
B-iv-bin-abs	1203	1206	133
B-outcome	1207	1213	breast
I-outcome	1214	1220	cancer
I-outcome	1221	1227	deaths
O	1228	1236	occurred
O	1237	1242	while
B-cv-bin-abs	1243	1246	896
B-outcome	1247	1253	breast
I-outcome	1254	1261	cancers
O	1262	1266	were
O	1267	1275	detected
O	1276	1279	and
B-cv-bin-abs	1280	1283	130
B-outcome	1284	1290	deaths
O	1291	1299	recorded
O	1300	1302	in
O	1303	1306	the
O	1307	1314	control
O	1315	1320	group
O	1320	1321	.

O	1322	1325	The
B-outcome	1326	1331	tumor
I-outcome	1332	1336	size
O	1337	1338	(
O	1338	1339	P
O	1340	1341	=
O	1342	1343	0
O	1343	1344	.
O	1344	1346	07
O	1346	1347	)
O	1347	1348	,
O	1349	1352	TNM
O	1353	1358	stage
O	1359	1360	(
O	1360	1361	P
O	1362	1363	=
O	1364	1365	0
O	1365	1366	.
O	1366	1368	39
O	1368	1369	)
O	1370	1373	and
B-outcome	1374	1384	cumulative
I-outcome	1385	1391	breast
I-outcome	1392	1398	cancer
I-outcome	1399	1408	mortality
I-outcome	1409	1413	rate
O	1414	1415	(
O	1415	1416	P
O	1417	1418	=
O	1419	1420	0
O	1420	1421	.
O	1421	1423	72
O	1423	1424	)
O	1425	1429	were
O	1430	1433	not
O	1434	1447	significantly
O	1448	1457	different
O	1458	1465	between
O	1466	1469	the
O	1470	1471	2
O	1472	1478	groups
O	1478	1479	.

O	1480	1487	However
O	1487	1488	,
O	1489	1493	more
O	1494	1497	and
O	1498	1505	smaller
B-outcome	1506	1519	fibroadenomas
O	1520	1524	were
O	1525	1533	detected
O	1534	1536	in
O	1537	1540	the
O	1541	1552	instruction
O	1553	1558	group
O	1559	1563	than
O	1564	1566	in
O	1567	1570	the
O	1571	1578	control
O	1579	1584	group
O	1585	1586	(
O	1586	1587	P
O	1587	1588	<
O	1589	1590	0
O	1590	1591	.
O	1591	1593	01
O	1593	1594	)
O	1594	1595	.

O	1596	1605	Intensive
O	1606	1617	instruction
O	1618	1620	in
O	1621	1624	BSE
O	1625	1628	did
O	1629	1632	not
O	1633	1637	seem
O	1638	1640	to
O	1641	1645	have
O	1646	1653	reduced
O	1654	1657	the
O	1658	1667	mortality
O	1668	1672	rate
O	1673	1675	of
O	1676	1682	breast
O	1683	1689	cancer
O	1689	1690	,
O	1691	1694	but
O	1695	1699	more
O	1700	1703	and
O	1704	1711	smaller
O	1712	1718	benign
O	1719	1725	breast
O	1726	1731	lumps
O	1732	1737	could
O	1738	1740	be
O	1741	1749	detected
O	1749	1750	.
